MDCC Molecular Devices (MM)

SUNNYVALE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Molecular Devices Corporation (NASDAQ:MDCC), a leader in innovative solutions for drug discovery and life sciences research, today announced the introduction of StakMax(TM), an integrated microplate handling system for its SpectraMax(R) line of microplate readers. The StakMax system enables researchers to run batches of microplates, which increases productivity by requiring less hands- on time during experiments. StakMax will debut today at the Annual Meeting of the Society for Biomolecular Sciences (SBS) in Seattle, Washington, in Molecular Devices Booth #2501. The StakMax system's small footprint makes it ideal for tight benchtop environments where automation is critical. The system can process up to 50 plates per batch and can be integrated with any Molecular Devices' SpectraMax reader sold today, as well as selected older readers. The new microplate handling system operates from within Molecular Devices' popular SoftMax(R) Pro microplate reader data analysis software, allowing researchers to have access to more than 120 assay protocols with complete data analysis. In addition, StakMax works with SoftMax Pro GxP to allow researchers to perform powerful data acquisition and analysis in a FDA 21 CFR Part 11 compliant environment. Commenting on the launch, Evan Baxter, Product Marketing Manager at Molecular Devices, stated, "StakMax was developed to satisfy automation needs not addressed by available automation options. We received considerable feedback from SpectraMax customers looking for a simple, reliable automation system that was operable through SoftMax Pro software. StakMax was developed so that researchers could easily setup and run an assay without having automation expertise." Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. This press release contains "forward-looking" statements, including statements related to the prospects for or potential customer use of the StakMax system. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of new products and their commercial acceptance, and other risks detailed from time to time in Molecular Devices' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. Molecular Devices Corporation does not undertake any obligation to update forward- looking statements. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/

Copyright